Human Genome Epidemiology Literature Finder
|
Records 1 - 26 (of 26 Records) |
| Query Trace: Inflammation and CYP2C19[original query] |
|---|
| Influences of proinflammatory and anti-inflammatory cytokine polymorphisms on eradication rates of clarithromycin-sensitive strains of Helicobacter pylori by triple therapy. Clinical pharmacology and therapeutics 2006 Jul 80 (1): 41-50. Sugimoto Mitsushige, Furuta Takahisa, Shirai Naohito, Ikuma Mutsuhiro, Hishida Akira, Ishizaki Takas |
| Clarithromycin resistance, tumor necrosis factor alpha gene polymorphism and mucosal inflammation affect H. pylori eradication success. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2007 Nov 11 (11): 1506-14; discussion 1514. Zambon Carlo-Federico, Fasolo Michela, Basso Daniela, D'Odorico Anna, Stranges Alessia, Navaglia Filippo, Fogar Paola, Greco Eliana, Schiavon Stefania, Padoan Andrea, Fadi Elisa, Sturniolo Giacomo Carlo, Plebani Mario, Pedrazzoli Serg |
| Genetic Polymorphism of CYP2C19 gene in the Stanislas cohort. A link with inflammation. Annals of human genetics 2008 Mar 72 (Pt 2): 178-83. Bertrand-Thiébault C, Berrahmoune H, Thompson A, Marie B, Droesch S, Siest G, Foernzler D, Visvikis-Siest |
| Association of interaction between smoking and CYP 2C19*3 polymorphism with coronary artery disease in a Uighur population. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2010 Oct 16 (5): 579-83. Yang Yi-Ning, Wang Xin-Lei, Ma Yi-Tong, Xie Xiang, Fu Zhen-Yan, Li Xiao-Mei, Chen Bang-Dang, Liu F |
| Influence of inflammatory cytokine polymorphisms on eradication rates of Helicobacter pylori. Journal of gastroenterology and hepatology 2009 Nov 24 (11): 1725-32. Sugimoto Mitsushige, Furuta Takahisa, Yamaoka Yosh |
| Antiplatelet resistance in outpatients with monitored adherence. Platelets 2014 25 (7): 532-8. Walter Philipp N, Tsakiris Dimitrios A, Romanens Michel, Arnet Isabelle, Hersberger Kurt |
| Effects of CYP2C19 Polymorphism on Endothelial Function, Arterial Stiffness and Inflammation in Coronary Artery Disease Patients Under Clopidogrel Treatment. Current pharmaceutical design 2015 Aug . Siasos Gerasimos, Zaromitidou Marina, Oikonomou Evangelos, Mourouzis Konstantinos, Tsalamandris Sotiris, Kioufis Stamatios, Kokkou Eleni, Zografos Theodoros, Antonopoulos Alexis, Dimitropoulos Stathis, Stefanadis Christodoulos, Papavassiliou Athanasios G, Tousoulis Dimitr |
| Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications. Current psychiatry reports 2015 Jul 17 (7): 50. Fabbri Chiara, Serretti Alessand |
| Helicobacter pylori virulence genes and host genetic polymorphisms as risk factors for peptic ulcer disease. Expert review of gastroenterology & hepatology 2015 Oct 1-13. Miftahussurur Muhammad, Yamaoka Yosh |
| Sex differences in the impact of CYP2C19 polymorphisms and low-grade inflammation on coronary microvascular disorder. American journal of physiology. Heart and circulatory physiology 2016 Mar ajpheart.00911.2015. Akasaka Tomonori, Hokimoto Seiji, Sueta Daisuke, Tabata Noriaki, Sakamoto Kenji, Yamamoto Eiichiro, Yamamuro Megumi, Tsujita Kenichi, Kojima Sunao, Kaikita Koichi, Kajiwara Ayami, Morita Kazunori, Oniki Kentaro, Saruwatari Junji, Nakagawa Kazuko, Ogata Yasuhiro, Ogawa His |
| Longitudinal Analysis of the Effect of Inflammation on Voriconazole Trough Concentrations. Antimicrobial agents and chemotherapy 2016 Feb . Encalada Ventura M A, van Wanrooy M J P, Span L F R, Rodgers M G G, van den Heuvel E R, Uges D R A, van der Werf T S, Kosterink J G W, Alffenaar J W |
| Decreased Activity and Genetic Polymorphisms of CYP2C19 in Behçet's Disease. Basic & clinical pharmacology & toxicology 2016 Nov . Goktas Mustafa Tugrul, Karaca R Ozgur, Kalkisim Said, Cevik Lokman, Kilic Levent, Akdogan Ali, Babaoglu Melih O, Bozkurt Atilla, Bertilsson Leif, Yasar Um |
| Pharmacogenetics may influence the impact of inflammation on voriconazole trough concentrations. Pharmacogenomics 2017 7 18 (12): 1119-1123. Gautier-Veyret Elodie, Bailly Sebastien, Fonrose Xavier, Tonini Julia, Chevalier Simon, Thiebaut-Bertrand Anne, Stanke-Labesque Françoi |
| CYP2C19 variants and epoxyeicosatrienoic acids in patients with microvascular angina. International journal of cardiology. Heart & vasculature 2017 Jun 15 15-20. Akasaka Tomonori, Sueta Daisuke, Arima Yuichiro, Tabata Noriaki, Takashio Seiji, Izumiya Yasuhiro, Yamamoto Eiichiro, Tsujita Kenichi, Kojima Sunao, Kaikita Koichi, Kajiwara Ayami, Morita Kazunori, Oniki Kentaro, Saruwatari Junji, Nakagawa Kazuko, Hokimoto Sei |
| Physiopathology and genetics in aspirin-exacerbated respiratory disease. Experimental lung research 2017 10 43 (8): 327-335. Pavón-Romero Gandhi F, Ramírez-Jiménez Fernando, Roldán-Alvarez Marco Alejandro, Terán Luis M, Falfán-Valencia Ramc |
| Evaluating the effect of type 2 diabetes mellitus on CYP450 enzymes and P-gp activities, before and after glycemic control: A protocol for a case-control pharmacokinetic study. MethodsX 2020 4 7 100853. Neyshaburinezhad Navid, Rouini Mohammadreza, Shirzad Nooshin, Esteghamati Alireza, Nakhjavani Manouchehr, Namazi Soha, Ardakani Yalda |
| Optimization of voriconazole therapy for treatment of invasive aspergillosis: Pharmacogenomics and inflammatory status need to be evaluated. British journal of clinical pharmacology 2020 Nov . Gautier-Veyret Elodie, Thiebaut-Bertrand Anne, Roustit Matthieu, Bolcato Léa, Depeisses Julie, Schacherer Mathilde, Schummer Gabriel, Fonrose Xavier, Stanke-Labesque Françoi |
| Differential effect of clopidogrel and ticagrelor on leukocyte count in relation to patient characteristics, biomarkers and genotype: a PLATO substudy. Platelets 2021 Jun 1-7. Nelson Thomas A, Parker William A E, Ghukasyan Lakic Tatevik, Westerbergh Johan, James Stefan K, Siegbahn Agneta, Becker Richard C, Himmelmann Anders, Wallentin Lars, Storey Robert |
| Antiplatelet and myocardial protective effect of Shexiang Tongxin Dropping Pill in patients undergoing percutaneous coronary intervention: A randomized controlled trial. Journal of integrative medicine 2022 Jan . Lin Yan-Jun, Jiao Kun-Li, Liu Bo, Fang Lu, Meng S |
| Individualized treatment with voriconazole in the Chinese population: inflammation level as a novel marker for dose optimization. British journal of clinical pharmacology 2023 9 . Xu Hao, Yuanyuan Li, Ying Zhang, Jialu Bian, Jinxia Zhao, Yinyu Zhao, Lei Hu, Xingxian Luo, Changqing Yang, Yufei Feng, Lin Hua |
| Association Between CYP2C19 Genotypes With Clinical Phenotypes and Adipokine Levels Among Ischemic Stroke Patients: A Prospective Observational Study. Cureus 2023 6 15 (5): e39265. Jitender Gairolla, Dheeraj Khurana, Phulen Sarma, Rupinder Kler, Bikash Medhi, Madhu Khullar, Manish Modi, Priyanka Naithani, Ashok Kum |
| The Role of Endoplasmic Reticulum Stress in Gastroesophageal Reflux Disease Symptoms and Treatment. The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology 2023 5 34 (5): 533-541. Elmas Kasap, Tahir Buran, Aysun Toraman Avcu, P?nar Solmaz Hasdemir, Erdal Balcan, Ça?da? Aktan, Mehmet Korkm |
| Influence of C-reactive protein on the pharmacokinetics of voriconazole in relation to the CYP2C19 genotype: a population pharmacokinetics analysis. Frontiers in pharmacology 2024 9 15 1455721. Jing Ling, Xuping Yang, Lulu Dong, Yan Jiang, Sulan Zou, Nan |
| Inflammation altered correlation between CYP2C19 genotype and CYP2C19 activity in patients receiving voriconazole. Clinical and translational science 2024 7 17 (7): e13887. Sylvia D Klomp, Anette Veringa, Jan-Willem C Alffenaar, Mark G J de Boer, Lambert F R Span, Henk-Jan Guchelaar, Jesse J Sw |
| Impact of CYP2C19 metabolizer status on esophageal mucosal inflammation, acid exposure, and motility among patients on chronic proton-pump inhibitor therapy with refractory symptoms of gastroesophageal reflux disease. Journal of the Canadian Association of Gastroenterology 2024 6 7 (3): 238-245. Cheng-Chun Tai, Samantha Medwid, Keith Mclntosh, Nilesh Chande, Richard B Kim, James Greg |
| CYP2C19 Poor Metabolizer Status and High System Inflammation Response Index are Independent Risk Factors for Premature Myocardial Infarction: A Hospital-Based Retrospective Study. International journal of general medicine 2024 11 17 4959-4969. Wendao Han, Nating Xiong, Renkai Zhong, Zhongyi P |
- Page last reviewed:Feb 1, 2024
- Content source: